Clazosentan clinical trials
Also written ACT-108475.
How each study uses clazosentan is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
7 studies that test it; most in 2018 (2)
| Year | Studies |
|---|---|
| 2005 | 1 |
| 2007 | 1 |
| 2009 | 1 |
| 2016 | 1 |
| 2018 | 2 |
| 2019 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 7 · Other 0
Often tested with
Tested in the same studies.
Related medicines
As reviewed, each with the page that says it.
Studies
Open first, then newest update. How each study uses clazosentan is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 7
- Clinical Research Study With Clazosentan to Evaluate Its Effects on Preventing Complications Due to the Narrowing of the Blood Vessels (Vasospasm) in the Brain, Caused by Bleeding Onto the Surface of the BrainCompletedPhase 3Idorsia Pharmaceuticals Ltd.NCT03585270Written as ClazosentanHow we know
- Clazosentan in Reducing Vasospasm-related Morbidity and All-cause Mortality in Adult Patients With Aneurysmal Subarachnoid Hemorrhage Treated by Surgical ClippingCompletedPhase 3Idorsia Pharmaceuticals Ltd.NCT00558311Written as ClazosentanHow we know
- A Study in Healthy Subjects to Investigate Whether Administration of Clazosentan Can Affect Normal Heart FunctionCompletedPhase 1Idorsia Pharmaceuticals Ltd.NCT03657446Written as ClazosentanHow we know
- A Study in Healthy Male Subjects to Investigate Whether Administration of Rifampicin Can Affect the Fate of Clazosentan in the Body of ClazosentanCompletedPhase 1Idorsia Pharmaceuticals Ltd.NCT03596294Written as ClazosentanHow we know
- Evaluation of the Efficacy and Safety of Clazosentan in Reversing Cerebral Vasospasm in Adult Subjects With Aneurysmal Subarachnoid HemorrhageCompletedPhase 2Idorsia Pharmaceuticals Ltd.NCT02560532Written as ClazosentanHow we know
- Clazosentan in Preventing the Occurrence of Cerebral Vasospasm Following an Aneurysmal Subarachnoid Hemorrhage (aSAH)CompletedPhase 2Idorsia Pharmaceuticals Ltd.NCT00111085Written as Clazosentan 1 mg/hHow we know
- Clazosentan in Aneurysmal Subarachnoid HemorrhageTerminatedPhase 3Idorsia Pharmaceuticals Ltd.NCT00940095Written as Clazosentan 5 m/hHow we know
Codes
What other systems call clazosentan · ClinicalTrials.gg INT004037
- MeSH (NLM) C109641clazosentanOne source NLM
- UNII (FDA) 3DRR0X4728CLAZOSENTANConfirmed FDA, NLM, Wikidata
- Wikidata Q1099339clazosentanConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C79486ClazosentanOne source FDA
- DrugBank DB06677One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C109641 | clazosentan | One source NLM |
| UNII (FDA) | 3DRR0X4728 | CLAZOSENTAN | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q1099339 | clazosentan | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C79486 | Clazosentan | One source FDA |
| DrugBank | DB06677 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.